scholarly journals The relationship between Fibroblast Growth Factor 23 (FGF23) and cardiac MRI findings following primary PCI in patients with acute first time STEMI

2021 ◽  
Vol 33 ◽  
pp. 100727
Author(s):  
Inga Strand Thorsen ◽  
Lasse G. Gøransson ◽  
Thor Ueland ◽  
Pål Aukrust ◽  
Cord A. Manhenke ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Cardiac Mri ◽  
Fibroblast Growth Factor 23 ◽  
Primary Pci ◽  
Fibroblast Growth ◽  
Mri Findings ◽  
First Time ◽  
The Relationship

scholarly journals FIBROBLAST GROWTH FACTOR-23 AND CARDIAC MRI INDICES OF MYOCARDIAL FIBROSIS IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS

2016 ◽  
Vol 67 (13) ◽  
pp. 1684
Author(s):  
Mohamed Faher Almahmoud ◽  
David Herrington ◽  
W. Hundley ◽  
Jennifer Jordan ◽  
Bryan Kestenbaum ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Myocardial Fibrosis ◽  
Cardiac Mri ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth ◽  
Ethnic Study

scholarly journals Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women

2011 ◽  
Vol 165 (5) ◽  
pp. 797-803 ◽  
Author(s):  
Mansi Dalal ◽  
Kai Sun ◽  
Anne R Cappola ◽  
Luigi Ferrucci ◽  
Candace Crasto ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Elevated Serum ◽  
Community Dwelling ◽  
Fibroblast Growth ◽  
Multivariable Logistic Regression Model ◽  
Cross Sectional ◽  
The Relationship

ObjectiveAlthough fibroblast growth factor 23 (FGF23) has been implicated in the pathogenesis of cardiovascular disease, the relationship between FGF23 and cardiovascular disease has not been well characterized in the general population. The aim of this study was to determine whether serum FGF23 is independently associated with cardiovascular disease in older community-dwelling women.Design and methodsA cross-sectional design was used to examine the relationship between serum FGF23 and cardiovascular disease. The subjects consisted of a population-based sample of 659 women, aged 70–79 years, who participated in the Women's Health and Aging Studies in Baltimore, Maryland. Prevalent cardiovascular disease (coronary heart disease, stroke, congestive heart failure, and peripheral artery disease) was assessed through diagnostic algorithms and physician adjudication.ResultsOf the 659 women, 185 (28.1%) had cardiovascular disease. Median (25th, 75th percentile) intact serum FGF23 was 34.6 (25.2, 46.2) pg/ml. The prevalence of cardiovascular disease in the lowest, middle, and highest tertile of serum FGF23 was 22.6, 24.9, and 36.7% respectively (P=0.002). Serum log FGF23 was associated with cardiovascular disease (odds ratio per 1s.d.increase=1.23, 95% confidence interval 1.17, 1.30;P<0.0001) in a multivariable logistic regression model, adjusting for age, race, smoking, education, body mass index, cognition, diabetes, hypertension, physical activity, total cholesterol, high-density lipoprotein cholesterol, and renal function.ConclusionElevated serum FGF23 concentrations are independently associated with prevalent cardiovascular disease in older community-dwelling women. Further studies are needed to elucidate the potential biological mechanisms by which FGF23 may be involved in the pathogenesis of cardiovascular disease.

Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?

2015 ◽  
Vol 48 (6) ◽  
pp. 431-436 ◽  
Author(s):  
Maria Bożentowicz-Wikarek ◽  
Piotr Kocełak ◽  
Aleksander Owczarek ◽  
Magdalena Olszanecka-Glinianowicz ◽  
Małgorzata Mossakowska ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Elderly Population ◽  
Iron Status ◽  
Fibroblast Growth Factor 23 ◽  
The Elderly ◽  
Fibroblast Growth ◽  
The Relationship

Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria

2016 ◽  
Vol 64 (6) ◽  
pp. 1128-1133 ◽  
Author(s):  
Ayca Inci ◽  
Funda Sari ◽  
Melahat Coban ◽  
Refik Olmaz ◽  
Suleyman Dolu ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Cross Sectional Study ◽  
Healthy Controls ◽  
Fibroblast Growth ◽  
Cross Sectional ◽  
Patients With Diabetes ◽  
The Relationship

The relationship between soluble Klotho (s-Klotho) levels, fibroblast growth factor 23 (FGF23) levels, and albuminuria in patients with diabetic chronic kidney disease (CKD) remains unclear. A total of 109 patients with type 2 diabetes (mean age 61.63±9.77 years), at the outpatient clinic of the Antalya Research and Training Hospital Nephrology Unit between January and June 2014, as well as 32 healthy controls (mean age 49.53±7.32 years) were enrolled for this cross-sectional study. Patients were classified into three groups according to their urinary albumin creatinine ratio (UACR), normoalbuminuria (UACR<30 mg/g), microalbuminuria (UACR 30–300 mg/g), and macroalbuminuria (UACR>300 mg/g). The blood was analyzed for FGF23, s-Klotho, parathyroid hormone (PTH), P, Ca, creatinine, and 25-hydroxyvitamin D3 (25hD) levels. Creatinine, s-Klotho, FGF23, and PTH levels were significantly higher and 25hD levels were significantly lower in the patient group than in the healthy controls (p<0.001). Between the groups according to UACR, 1-way analysis of variance revealed statistically significant differences for creatinine (p<0.001), 25hD (p<0.001), PTH (p=0.002), Ca (p=0.002), and albumin levels (p<0.001). A statistically significant positive correlation was found between s-Klotho and FGF23 (r=0.768; p=0.001), and between FGF23 levels and UACR (r=0.768; p=0.001). In conclusion, the results of the present study suggest that s-Klotho levels are significantly elevated in patients with diabetes and s-Klotho levels decreased with increasing albumin excretion in our patients despite a reduction in estimated glomerular filtration rate.

scholarly journals Tumour Induced Osteomalacia: Rapid Clinical and Biochemical Control Using Octreotide

2020 ◽  
pp. 58-64
Author(s):  
Omayma Elshafie ◽  
Ali Al Magbali ◽  
Nicholas Woodhouse
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Serum Calcium ◽  
Fibroblast Growth Factor 23 ◽  
Parathyroid Hyperplasia ◽  
Fibroblast Growth ◽  
Mri Findings ◽  
Short Acting ◽  
Focal Uptake ◽  
Fgf 23

Aims: To assess the effects of short acting octreotide on the Fibroblast Growth Factor-23 levels and the clinical outcome in a bedridden patient with Tumour Induced Osteomalacia. Presentation of the Case: A 40-year old female, presented with a 16-year history of progressive weakness and bone pains. Severe hypophosphatemia had been documented throughout and she had been treated intermittently with oral phosphate and various preparation of vitamin D.  Hypercalcaemia due to parathyroid hyperplasia was diagnosed 4 years previously. In the last 2 years she had undergone bilateral hip prostheses and removal of 2 hyperplastic parathyroid glands. When seen by us she was bedbound with severe restriction of all joint movements, there was a palpable left buttock mass 4x4 cm. Tumour induced osteomalacia was suspected and confirmed by finding grossly elevated levels of Fibroblast growth factor (FGF-23) 3400 Ru/ml (44-140).The serum calcium 2.5 mmol/L (n 2.1-2.5), phosphate 0.3 mmol/L  (n 0.8-1.45).Alkaline phosphatase (ALP) 400 U/L ( n 35-104), Parathyroid hormone (PTH) 27 pmol/L (n 1.6-9.3) , and creatinine 70 umol/L (n 45-84). Octreotide scanning revealed focal uptake in the buttock corresponding to the MRI findings. Treatment with octreotide 100 mcg 8 hourly was given for 10 days before surgery. By day 3 the FGF-23 had fallen to 400 and on the day of surgery was 210 Ru/ml. A benign mesenchymal tumour was completely resected and 8 weeks following surgery the FGF-23 was normal, serum calcium 2.7 mmol/L, serum phosphorus 0.63 mmol/L, ALP 690 U/L, PTH 22 pmol/L . The patient was then able to walk in a Zimmer frame after 2 months. Since then she recovered completely, she is able to walk without assistance for the last 2 years. Conclusion: This case provides an example of successful use of short acting octreotide in controlling the disease and demonstrated a rapid normalisation of elevated FGF-23 levels achieved during treatment with octreotide. It describes a rare association between tumour induced osteomalacia (TIO) and parathyroid hyperplasia, the value of octreotide scanning in tumour localisation and the potential for using LA octreotide therapy in patients with responsive tumours that cannot be localised or removed for any reason.

Sign in / Sign up

Export Citation Format

Share Document